Gufic Biosciences Limited will host an earnings conference call for investors and analysts on Monday, August 17, 2026, at 04:30 p.m. (IST). The session is intended to provide stakeholders with insights into the company's business background, future prospects, and recent financial performance. Officials from the company will also address questions from participants during the call. This disclosure was made pursuant to Regulation 30 read with Part A of Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The company notified both the Bombay Stock Exchange (BSE) and the National Stock Exchange of India Limited (NSE) regarding the event. The intimation, signed by Ami Shah, Company Secretary & Compliance Officer, was issued on August 11, 2026. The notice ensures that market participants are aware of the upcoming discussion platform where management will elaborate on operational updates and financial outcomes.

Conference Call Details

Participants can join the earnings call via pre-registration or through dedicated dial-in numbers provided for various regions. The company has facilitated access for domestic and international investors by listing contact numbers for India, the United States, the United Kingdom, Singapore, and Hong Kong.

Investors are advised to use the pre-registration link provided in the official invitation to ensure seamless access to the virtual meeting platform. The call invite includes all necessary technical details for joining the session.

Regulatory Compliance

The announcement adheres to the mandatory disclosure norms set by the Securities and Exchange Board of India (SEBI). By hosting this conference call, Gufic Biosciences Limited fulfills its obligation to communicate material information to its shareholders and the investing public promptly. The Company Secretary confirmed the details with a digital signature dated August 11, 2026, ensuring the authenticity of the communication sent to the stock exchanges.

The Board of Directors of Gufic Biosciences has approved the re-appointment of Pankaj Jayakumar Gandhi as Whole Time Director for a further term of five years. The decision, taken during a board meeting on July 31, 2026, secures leadership continuity for the pharmaceutical company through September 06, 2031. The re-appointment is subject to approval by shareholders at the ensuing 42nd Annual General Meeting.

The appointment was made pursuant to Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Board also confirmed compliance with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. Mr. Gandhi is not debarred from holding the office of Director by any order passed by the Securities and Exchange Board of India (SEBI) or any other authority.

Key Appointment Details

Leadership Profile

Pankaj Jayakumar Gandhi holds a Bachelor's degree in Commerce from the University of Mumbai. He brings over three decades of experience in liaising with regulatory authorities within the pharmaceutical industry. His role focuses on ensuring regulatory compliance and maintaining effective coordination with statutory bodies. Management notes that his expertise has contributed significantly to the operational efficiency of Gufic Biosciences.

Regulatory Compliance

The company disclosed that Mr. Gandhi is not related to any other Directors of the Company. The Board meeting commenced at 04:30 p.m. and concluded at 06:25 p.m. on July 31, 2026. The announcement was signed by Ami Shah, Company Secretary & Compliance Officer (Membership No. A39579).